Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The N-terminal ricin-B domain of LSLa (Laetiporus sulphureus lectin) is a carbohydrate-binding module found in the hemolytic toxin produced by the mushroom Laetiporus sulphureus (Tateno & Goldstein, 2003). This domain adopts a beta-trefoil fold, characteristic of the ricin-B family, and is responsible for the specific recognition and binding of the toxin to cell surface glycoconjugates containing galactose or N-acetylgalactosamine (Mancheño et al., 2005). While the C-terminal domain of LSLa is responsible for membrane insertion and pore formation, the N-terminal domain is crucial for targeting the toxin to the host cell membrane (UniProt P83406). In a research context, this domain is studied for its potential in glycan profiling and as a delivery vehicle for targeting specific cell types, although it is not a conventional therapeutic target. Its primary biological role is as a component of a fungal defense or predatory toxin that induces hemolysis and cell death. There are currently no approved drugs targeting this domain, but small-molecule carbohydrates can act as competitive inhibitors of its binding activity in experimental settings. Structural studies have revealed that the domain forms a hexameric assembly in the context of the full toxin, which is essential for its pore-forming efficiency.
Competitive inhibition of carbohydrate binding by specific sugars such as lactose or N-acetylgalactosamine
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Laetiporus sulphureus lectin N-terminal ricin-B-like domain (LSL-N).